{"id":"W4281936531","doi":"10.1200/jco.2022.40.16_suppl.105","title":"Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Cancer; Phases of clinical research; Internal medicine; Oncology; Population; Response Evaluation Criteria in Solid Tumors; Antibody; Stage (stratigraphy); Clinical trial; Cancer research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006641677,0.0002864523,0.0005319706,0.0002077052,0.0001762297,0.0005050811,0.0002664276,0.0004496826,0.001804935],"category_scores_gemma":[0.0004880953,0.0001356563,0.0005849428,0.0002078861,0.0003331199,0.0004139353,0.0001597207,0.000841616,0.0003154895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000987758,"about_ca_system_score_gemma":0.0007097434,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001433364,"about_ca_topic_score_gemma":0.002479262,"domain_scores_codex":[0.9998199,0.00005947567,0.00001267275,0.00003258737,0.00003153083,0.00004378374],"domain_scores_gemma":[0.999761,0.0000452626,0.00005640601,0.00001505135,0.00001696496,0.0001053693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4705608,0.02512817,0.03244833,0.0007099426,0.0009156091,0.0005108821,0.0002900787,0.007030407,0.1127412,0.0005794847,0.006784914,0.3423002],"study_design_scores_gemma":[0.09195457,0.6885251,0.1708006,0.00008010256,0.001205244,0.001393788,0.0001074041,0.006940879,0.0271834,0.0004177531,0.01134789,0.00004333999],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949567,0.001651475,0.0003116508,0.0001231709,0.0000301446,0.0002489044,0.0005329731,0.00004458513,0.002100386],"genre_scores_gemma":[0.9975984,0.0004457425,0.0002360071,0.00011381,0.00002448579,0.00007427589,0.0007463717,0.000007197621,0.0007537364],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001804935,"threshold_uncertainty_score":0.007166684,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.151673482308748,"score_gpt":0.5658398469977208,"score_spread":0.4141663646889728,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}